After the combination therapy of anti-PD-L1 and anti-VEGFR2 for two weeks, the expression levels of IFN-γ+CD8+ and IFN-γ+CD4+ T cells were dramatically boosted in the pancreatic neuroendocrine tumor and mammary carcinoma, whereas the number of IFN-γ+CD8+ T cells was only modestly elevated for approximately 50% in glioblastomas (195). The gene discussed is CD8A; the disease is pancreatic neuroendocrine tumor.